TSVT 2SEVENTY BIO INC revenue, earnings and financials
For the quarter ended March 31, 2025, 2SEVENTY BIO INC reported revenue of $22.9M (up 84.5% from a year earlier), net income of $482K and diluted EPS of $0.01; over the last four quarters revenue was $48.4M and net income −$4.09M; for the fiscal year ended December 2024 revenue was $37.9M, down 62.3% on the year before.
TSVT annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $37.9M, gross profit n/a, operating income −$115M, net income −$57.2M (margin -151.2%), EPS −$1.10
- Fiscal year ended Dec 2023: revenue $100M, gross profit n/a, operating income −$238M, net income −$218M (margin -216.7%), EPS −$4.42
- Fiscal year ended Dec 2022: revenue $91.5M, gross profit n/a, operating income −$263M, net income −$254M (margin -277.8%), EPS −$7.13
- Fiscal year ended Dec 2021: revenue $54.5M, gross profit n/a, operating income −$314M, net income −$292M (margin -536.0%), EPS −$12.44
TSVT quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue $22.9M (up 84.5% year over year), net income $482K, EPS $0.01
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.93M (down 72.6% year over year), net income −$19.5M, EPS −$0.35
- Quarter ended Sep 30, 2024: revenue $13.5M (up 12.5% year over year), net income −$9.93M, EPS −$0.19
- Quarter ended Jun 30, 2024: revenue $8.97M (down 75.1% year over year), net income $24.9M, EPS $0.45
- Quarter ended Mar 31, 2024: revenue $12.4M (down 70.1% year over year), net income −$52.7M, EPS −$1.01
- Quarter ended Dec 31, 2023 (from the annual report): revenue $10.7M (down 81.0% year over year), net income −$56.8M, EPS −$1.11
- Quarter ended Sep 30, 2023: revenue $12.0M (down 10.2% year over year), net income −$71.6M, EPS −$1.40
- Quarter ended Jun 30, 2023: revenue $36.0M (up 167.4% year over year), net income −$42.1M, EPS −$0.83
- Quarter ended Mar 31, 2023: revenue $41.6M (up 393.8% year over year), net income −$47.0M, EPS −$1.08
- Quarter ended Dec 31, 2022 (from the annual report): revenue $56.2M (up 250.3% year over year), net income −$23.1M, EPS −$0.15
- Quarter ended Sep 30, 2022: revenue $13.4M (down 30.4% year over year), net income −$67.9M, EPS −$1.76
- Quarter ended Jun 30, 2022: revenue $13.5M (up 84.0% year over year), net income −$77.4M, EPS −$2.02
- Quarter ended Mar 31, 2022: revenue $8.43M (down 29.2% year over year), net income −$85.7M, EPS −$3.20
- Quarter ended Dec 31, 2021 (from the annual report): revenue $16.0M, net income −$61.0M, EPS −$2.54
- Quarter ended Sep 30, 2021: revenue $19.3M, net income −$60.0M, EPS −$2.57
- Quarter ended Jun 30, 2021: revenue $7.33M, net income −$84.0M, EPS −$3.60
- Quarter ended Mar 31, 2021: revenue $11.9M, net income −$87.2M, EPS −$3.73
TSVT cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$85.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$167M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$228M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$207M, share buybacks n/a
TSVT balance sheet
- Mar 31, 2025: cash $92.4M, total assets $480M, total liabilities $266M, shareholders' equity $214M
- Dec 31, 2024: cash $71.2M, total assets $480M, total liabilities $269M, shareholders' equity $211M
- Sep 30, 2024: cash $60.0M, total assets $504M, total liabilities $276M, shareholders' equity $228M
- Jun 30, 2024: cash $112M, total assets $518M, total liabilities $283M, shareholders' equity $235M
- Mar 31, 2024: cash $56.8M, total assets $511M, total liabilities $304M, shareholders' equity $207M
- Dec 31, 2023: cash $75.0M, total assets $565M, total liabilities $310M, shareholders' equity $255M
- Sep 30, 2023: cash $90.2M, total assets $641M, total liabilities $334M, shareholders' equity $306M
- Jun 30, 2023: cash $96.0M, total assets $706M, total liabilities $338M, shareholders' equity $367M
What is TSVT's revenue?
2SEVENTY BIO INC reported $48.4M of revenue over its last four quarters, through March 31, 2025.
Is TSVT profitable?
No. 2SEVENTY BIO INC lost $4.09M over the last four quarters.
What is TSVT's EPS?
Diluted earnings per share over the last four quarters were −$0.08; $0.01 in the latest quarter.